The goal of the visual outcome working group is to define the best outcome measures for use in clinical trials of NF1 associated optic pathway gliomas (OPG). Our group assesses psychophysical components of vision, other ophthalmologic elements affected by OPG, potential biomarkers of visual function, and quality of life measures to arrive at consensus-based, evidence-driven recommendations.
Current group co-leaders: Rob Avery, MD and Michael Fisher, MD
Past group leader: Michael Fisher, MD
1. Fisher MJ, Avery RA, Allen JC, et al. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 2013 Nov 19;81:(21 Suppl 1)S15-S24. [PDF]